S&P 5007,533.77▼0.5% Nasdaq25,881.95▼1.5% Dow52,552.97▼0.2% Russell 2K2,974.57▼0.1% 10-Yr4.57%+2bp VIX16.73+1.06 WTI$79.00▼0.8% Gold$3,981.40▼1.6% EUR/USD1.145▼0.2% BTC$65,138▲0.7% Nikkei68,752▲1.5%
At close · Thu, Jul 16, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›Samsung Biologics makes $1.8 billion all-cash bid for…

Samsung Biologics makes $1.8 billion all-cash bid for PolyPeptide

The offer values PolyPeptide at 1.46 billion Swiss francs, or about $1.8 billion, and is structured as an all-cash transaction.

Reported · Written up by our desk · M&A & Deals

Samsung Biologics has made an all-cash bid for Switzerland-based PolyPeptide Group, according to CNBC Markets. The proposed deal is for 1.46 billion Swiss francs, which CNBC World reported as equivalent to about $1.8 billion.

Samsung Biologics said the offer is 100% cash, reflecting a fully cash transaction structure for the acquisition.

← Newer storyTrump tells Carney Canada must do more on Ontario wildfire smoke

More like this

US MarketsBloom Energy signs $1.7 billion fuel cell deal for Nebius AI power
US MarketsLionsgate shares jump on takeover speculation involving multiple suitors
US MarketsJudge pauses Paramount and Warner merger for at least two weeks
US MarketsParamount and Warner Bros. merger faces temporary restraining order
US MarketsJudge temporarily pauses Paramount-Warner Bros. merger

Sources

CNBC MarketsSamsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group
CNBC WorldSamsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.